AU2004285855B8 - Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl) -5 -pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone - Google Patents

Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl) -5 -pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone Download PDF

Info

Publication number
AU2004285855B8
AU2004285855B8 AU2004285855A AU2004285855A AU2004285855B8 AU 2004285855 B8 AU2004285855 B8 AU 2004285855B8 AU 2004285855 A AU2004285855 A AU 2004285855A AU 2004285855 A AU2004285855 A AU 2004285855A AU 2004285855 B8 AU2004285855 B8 AU 2004285855B8
Authority
AU
Australia
Prior art keywords
pyridin
chlorophenyl
methanone
triazol
bistrifluoromethylbenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004285855A
Other languages
English (en)
Other versions
AU2004285855A1 (en
AU2004285855B2 (en
Inventor
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Shella Lenyonga Tameze
Carsten Timpe
Carsten Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2004285855A1 publication Critical patent/AU2004285855A1/en
Application granted granted Critical
Publication of AU2004285855B2 publication Critical patent/AU2004285855B2/en
Publication of AU2004285855B8 publication Critical patent/AU2004285855B8/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2004285855A 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl) -5 -pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone Expired AU2004285855B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
US60/514,300 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (3)

Publication Number Publication Date
AU2004285855A1 AU2004285855A1 (en) 2005-05-12
AU2004285855B2 AU2004285855B2 (en) 2010-12-23
AU2004285855B8 true AU2004285855B8 (en) 2011-04-28

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004285855A Expired AU2004285855B8 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl) -5 -pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Country Status (28)

Country Link
US (1) US7381826B2 (cg-RX-API-DMAC10.html)
JP (1) JP4959336B2 (cg-RX-API-DMAC10.html)
KR (1) KR100848407B1 (cg-RX-API-DMAC10.html)
CN (1) CN1863791B (cg-RX-API-DMAC10.html)
AR (1) AR046131A1 (cg-RX-API-DMAC10.html)
AT (1) ATE462700T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004285855B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0415010B8 (cg-RX-API-DMAC10.html)
CA (1) CA2542140C (cg-RX-API-DMAC10.html)
CL (2) CL2009001311A1 (cg-RX-API-DMAC10.html)
CR (1) CR8353A (cg-RX-API-DMAC10.html)
DE (1) DE602004026333D1 (cg-RX-API-DMAC10.html)
DK (1) DK1675846T3 (cg-RX-API-DMAC10.html)
EA (1) EA008881B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP066517A (cg-RX-API-DMAC10.html)
ES (1) ES2340772T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20100207T1 (cg-RX-API-DMAC10.html)
IL (1) IL174926A0 (cg-RX-API-DMAC10.html)
MA (1) MA28329A1 (cg-RX-API-DMAC10.html)
MY (1) MY157375A (cg-RX-API-DMAC10.html)
NO (1) NO335090B1 (cg-RX-API-DMAC10.html)
NZ (2) NZ545917A (cg-RX-API-DMAC10.html)
PE (1) PE20050481A1 (cg-RX-API-DMAC10.html)
PT (1) PT1675846E (cg-RX-API-DMAC10.html)
TW (1) TW200524906A (cg-RX-API-DMAC10.html)
UA (1) UA82901C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005042515A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200603234B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121610B1 (en) * 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant
WO2026152024A1 (en) 2025-01-09 2026-07-16 Vanda Pharmaceuticals Inc. Method of treating nausea and vomiting after glp-1r agonist administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
DE60039616D1 (de) * 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
WO2001032656A1 (en) * 1999-10-29 2001-05-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
AU2003230829B8 (en) * 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Also Published As

Publication number Publication date
NZ580480A (en) 2010-02-26
CA2542140A1 (en) 2005-05-12
KR100848407B1 (ko) 2008-07-28
AR046131A1 (es) 2005-11-23
DE602004026333D1 (de) 2010-05-12
PT1675846E (pt) 2010-04-20
EA008881B1 (ru) 2007-08-31
US20070078166A1 (en) 2007-04-05
CL2009001310A1 (es) 2009-12-04
CN1863791B (zh) 2011-12-07
DK1675846T3 (da) 2010-05-31
NZ545917A (en) 2009-11-27
BRPI0415010B8 (pt) 2021-05-25
AU2004285855A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
EA200600829A1 (ru) 2006-08-25
NO335090B1 (no) 2014-09-08
JP4959336B2 (ja) 2012-06-20
CL2009001311A1 (es) 2009-10-02
TW200524906A (en) 2005-08-01
ZA200603234B (en) 2007-07-25
IL174926A0 (en) 2006-08-20
BRPI0415010B1 (pt) 2019-07-09
WO2005042515A1 (en) 2005-05-12
PE20050481A1 (es) 2005-09-20
ATE462700T1 (de) 2010-04-15
US7381826B2 (en) 2008-06-03
HRP20100207T1 (hr) 2010-05-31
CN1863791A (zh) 2006-11-15
ES2340772T3 (es) 2010-06-09
JP2007509143A (ja) 2007-04-12
ECSP066517A (es) 2006-10-10
BRPI0415010A8 (pt) 2018-05-08
CR8353A (es) 2006-06-06
MA28329A1 (fr) 2006-12-01
MY157375A (en) 2016-06-15
UA82901C2 (en) 2008-05-26
KR20060061388A (ko) 2006-06-07
BRPI0415010A (pt) 2006-11-07
AU2004285855B2 (en) 2010-12-23
CA2542140C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
AU2004285855B2 (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl) -5 -pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP6254075B2 (ja) カリウムチャネル遮断剤としてのアミン誘導体
EP3580220B1 (en) Aminotriazolopyridines as kinase inhibitors
JP4732354B2 (ja) グリシン輸送阻害薬としての二環式[3.1.0]誘導体
EP2121610B1 (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
EP3996713B1 (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate
CN101896461A (zh) γ分泌酶调节剂
NZ547164A (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl]benzamide, preparation and therapeutic use thereof
JP5587246B2 (ja) レニン阻害剤としての3,4−置換ピペリジン誘導体
SK17222002A3 (sk) Inhibítory serínových proteáz
EP3334721B1 (en) Cgrp receptor antagonists
KR100245955B1 (ko) 메타노안트라센화합물
AU2021410119A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
US5512575A (en) Methanoanthraceneyl methyl piperidinyl compounds
EP1675846B1 (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h- [1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
MXPA06004444A (en) Novel crystalline forms of {2-[1-(3, 5-bis-trifluoromethylbenzyl) -5-pyridin-4-yl -1h-[1, 2, 3]triazol -4-yl]- pyridin-3-yl}- (2-chlorophenyl) -methanone
HK40064417A (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate
HK40064417B (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 24, NO 51, PAGE(S) 5988 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ELI LILLY AND COMPANY, APPLICATION NO. 2004285855, UNDER INID (54) CORRECT THE TITLE TO READ NOVEL CRYSTALLINE FORMS OF {2-[1-(3,5-BIS-TRIFLUOROMETHYLBENZYL) -5 - PYRIDIN- 4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-CHLOROPHENYL)-METHANONE

MK14 Patent ceased section 143(a) (annual fees not paid) or expired